Advanced/Metastatic Solid Tumors

Oncology
10
Pipeline Programs
5
Companies
10
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Adagene
AdageneJIANGSU, China
5 programs
3
2
ADG126Phase 1/21 trial
ADG126 MonoPhase 1/21 trial
ADG116Phase 11 trial
ADG116Phase 11 trial
ADG206Phase 11 trial
Active Trials
NCT04501276Completed72Est. Nov 2025
NCT05277402Completed6Est. Dec 2022
NCT05614258Active Not Recruiting14Est. Aug 2026
+2 more trials
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
MHB088C for InjectionPhase 1/21 trial
Active Trials
NCT07102004RecruitingEst. Jul 2027
Pfizer
PfizerNEW YORK, NY
2 programs
2
PF-05082566Phase 11 trial
PF-08046876Phase 11 trial
Active Trials
NCT02444793Terminated24Est. Oct 2017
NCT07090499Recruiting310Est. Jul 2029
Antengene
AntengeneChina - Shanghai
1 program
1
ATG-022Phase 11 trial
Active Trials
NCT05718895RecruitingEst. Jun 2026
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
SelicrelumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT02665416Completed94Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Qilu PharmaceuticalMHB088C for Injection
AdageneADG126
AdageneADG126 Mono
PfizerPF-08046876
AntengeneATG-022
AdageneADG206
AdageneADG116
AdageneADG116
RocheSelicrelumab
PfizerPF-05082566

Clinical Trials (10)

Total enrollment: 764 patients across 10 trials

NCT07102004Qilu PharmaceuticalMHB088C for Injection

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

Start: Jun 2023Est. completion: Jul 2027
Phase 1/2Recruiting
NCT05405595AdageneADG126

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start: Jun 2022Est. completion: Apr 2027186 patients
Phase 1/2Recruiting
NCT04645069AdageneADG126 Mono

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Start: Mar 2021Est. completion: May 202458 patients
Phase 1/2Completed
NCT07090499PfizerPF-08046876

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Start: Aug 2025Est. completion: Jul 2029310 patients
Phase 1Recruiting
NCT05718895AntengeneATG-022

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Start: Mar 2023Est. completion: Jun 2026
Phase 1Recruiting
NCT05614258AdageneADG206

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Start: Feb 2023Est. completion: Aug 202614 patients
Phase 1Active Not Recruiting
NCT05277402AdageneADG116

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start: Feb 2022Est. completion: Dec 20226 patients
Phase 1Completed
NCT04501276AdageneADG116

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Start: Sep 2020Est. completion: Nov 202572 patients
Phase 1Completed
NCT02665416RocheSelicrelumab

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Start: Jan 2016Est. completion: Oct 201994 patients
Phase 1Completed
NCT02444793PfizerPF-05082566

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Start: May 2015Est. completion: Oct 201724 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 764 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)